Roche (SIX:ROG; OTCQX:RHHBY) said 1H11 global sales of Avastin bevacizumab fell due to ongoing regulatory uncertainty, while U.S. sales of Lucentis ranibizumab in wet age-related macular degeneration (AMD)
Read the full 289 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury